Medy-Tox

메디톡스 · 086900

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$459.6M (₩634.2B)

Overview

Medy-Tox is a South Korean pharmaceutical and biotechnology company best known for making botulinum toxin products, injectable treatments used to reduce wrinkles and address certain medical conditions.

Its products are used by medical professionals in aesthetic and therapeutic settings. The company is listed on KOSDAQ, South Korea's technology and small-cap stock exchange.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$179.2M

▲ +8.2% YoY

Operating profit · FY2025

US$12.3M

▼ −16.4% YoY

Net income · FY2025

US$11.3M

▼ −2.6% YoY

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$160.2M(₩221.1B)	US$165.7M(₩228.6B)	US$179.2M(₩247.3B)
Operating profit	US$12.6M(₩17.3B)	US$14.7M(₩20.3B)	US$12.3M(₩17B)
Net income	US$7M(₩9.7B)	US$11.6M(₩16.1B)	US$11.3M(₩15.7B)

Revenue

FY2023US$160.2M
FY2024US$165.7M
FY2025US$179.2M

Operating profit

FY2023US$12.6M
FY2024US$14.7M
FY2025US$12.3M

Net income

FY2023US$7M
FY2024US$11.6M
FY2025US$11.3M

Key ratios (FY2025)

ROE

3.5%

Debt/Eq

28.1%

Op. margin

6.9%

Net margin

6.3%

Rev. YoY

▲ +8.2%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?